Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Applicable to Multiple Industries

• Active investigation phase in the EU, Canada, China, Japan and India
• Forming four new wholly owned subsidiaries
• Seeks to acquire an equitable tax treatment

Cannabinoids are poorly absorbed by the body’s gastrointestinal tract, a trait that Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) lipophilic enhancement technology DehydraTECH™ is changing. Previously, consumers have turned to cannabis smoking to achieve higher effectiveness. However, human clinical studies have shown DehydraTECH™ to have a quick rate of absorption, allowing users to avoid the risks associated with smoking. DehydraTECH™ offers improved taste and smell, with effects felt within 15 to 20 minutes as opposed to the 60-120 minutes associated with traditional ingestion methods. This edible technology is patent-protected for CBD and all other cannabinoids, with the potential to revolutionize additional industries.

Lexaria is a biotechnology company that out-licenses its disruptive delivery technology promoting healthier ingestion methods. The company is the only one worldwide that has patents in the U.S. and Australia, with more pending in 40 countries for improved delivery of all non-psychoactive cannabinoids. The technology is in the active investigation phase in the EU, Canada, China, Japan and India.

DehydraTECH™ applies to far more than cannabinoids and is patented or patent-pending for use with a broad range of bioactive molecules. Last year, the company received its first patent on nicotine, ibuprofen and aspirin delivery in the U.S. This enabling technology has far-reaching implications and can be used to improve existing products or create new ones.

Currently, the company is forming four new wholly owned subsidiaries, one each for the pharmaceutical, nicotine, hemp and cannabis industries. Each subsidiary will take full advantage of DehydraTECH™ patent absorption technology and its applications to the related industry sector. In a recent Uptick Newswire podcast interview, Chris Bunka, CEO of LXRP, indicated that up to 80 percent of total revenue for the company will come from licensing deals (http://ibn.fm/mr9nr). Creating subsidiaries for separate industry sectors is expected to greatly assist in the research and development and financial growth of LXRP.

Previous plans to convert the company from being U.S.-based to Canada-based have been put on hold as the company seeks to acquire an equitable tax treatment following news that some shareholders may be adversely affected by punitive taxes upon the conversion.

For more information, visit the company’s website at www.LexariaBioscience.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php